Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation
Authors:
- Francesco PallanteFPFrancesco Pallante
- Francesco CostaFCFrancesco Costa
- Victoria Garcia RuizVRVictoria Garcia Ruiz
- Giampiero VizzariGiampiero Vizzari
- Pietro IannelloPIPietro Iannello
- Lucio TeresiLTLucio Teresi
- Gabriele CarciottoGCGabriele Carciotto
- Stefania Lo GiudiceSGStefania Lo Giudice
- Giustina IuvaraGIGiustina Iuvara
- Giulia LaterraGLGiulia Laterra
- Ander RegueiroARAnder Regueiro
- Gennaro GiustinoGGGennaro Giustino
Open Access
- 21 June 2024
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3636
Abstract
Transcatheter aortic valve implantation (TAVI) now represents the mainstay of treatment for severe aortic stenosis. Owing to its exceptional procedural efficacy and safety, TAVI has been extended to include patients at lower surgical risk, thus now encompassing a diverse patient population receiving this treatment. Yet, long-term outcomes also depend on optimal medical therapy for secondary vascular prevention, with antithrombotic therapy serving as the cornerstone. Leveraging data from multiple randomized controlled trials, the current guidelines generally recommend single antithrombotic therapy, with either single antiplatelet therapy (SAPT) or oral anticoagulation (OAC) alone in those patients without or with atrial fibrillation, respectively. Yet, individualization of this pattern, as well as specific case uses, may be needed based on individual patient characteristics and concurrent procedures. This review aims to discuss the evidence supporting antithrombotic treatments in patients treated with TAVI, indications for a standardized treatment, as well as specific considerations for an individualized approach to treatment.Keywords
All Related Versions
This publication has 82 references indexed in Scilit:
- Rationale and design of Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation (NAPT) TrialContemporary Clinical Trials, 2023
- Evolving concepts in the management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantationEuropean Journal of Internal Medicine, 2022
- Periprocedural Myocardial Injury and Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve ReplacementCardiovascular Revascularization Medicine, 2022
- Single Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Clinical TrialsCardiovascular Revascularization Medicine, 2022
- Deep Learning: A Comprehensive Overview on Techniques, Taxonomy, Applications and Research DirectionsSN Computer Science, 2021
- Impact of bioprosthetic valve type on peri-procedural myocardial injury and mortality after transcatheter aortic valve replacementHeart and Vessels, 2021
- Incidence, Predictors, Management, and Clinical Significance of New-Onset Atrial Fibrillation After Transcatheter Aortic Valve ImplantationThe American Journal of Cardiology, 2019
- Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry)The American Journal of Cardiology, 2018
- Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trialAmerican Heart Journal, 2018
- Secundum Atrial Septal DefectJAMA, 1976